With the progress of science and technology, biotechnology is more and more applied in the treatment of diseases, today we will introduce the latest new technology for the treatment of tumors —— endosomal secretory expression of apoptotic tumor peptide technology. To understand this technology, we have to know what is peptide first? As we all know, protein is the basic organic substance that constitutes cells and is the main bearer of life activities. And amino acids are the basic building blocks of proteins. In the process of forming proteins, amino acids first combine with each other to form peptide chains, more than 10 amino acids are called peptides, and one or more peptide chains form proteins. With the in-depth study of proteins, it is found that different proteins have different functions because of the different special structural regions of specific amino acid sequences in their molecular structures, and this special structural region can still function even if it is separated from the protein. Such amino acid sequence with specific function is called “bioactive short peptide” (hereinafter referred to as “active peptide”). In other words, bioactive short peptides can be separated from proteins and perform specific functions alone. They are diverse, simple in structure and small in molecular weight, and can regulate almost all functions of all cells. Different active peptides have specificity of action sites and precise localization. They play an important role in cell signaling, cell metabolism and proliferation, apoptosis, cell differentiation and transformation, and more and more studies prove their clinical application in malignant tumors, cardiovascular and cerebrovascular diseases, central nervous degeneration, severe infections and other diseases. How does apoptosis peptide technology play a role in tumor treatment? We all know that malignant tumor is different from normal human body because tumor cells are uncontrolled and have the characteristics of unlimited growth, local infiltration and distant metastasis. Under normal circumstances, the cells in human body produce active peptides to regulate the abnormal cells, either to restore the abnormal cells to normal or to remove the abnormal cells directly by apoptosis, so as to achieve the role of protecting human body. It has been found that in tumor patients, there is a decrease or loss of this ability, resulting in the uncontrolled “crazy growth” of tumor cells. At present, many active peptides have been discovered internationally that are specific for inducing apoptosis or directly killing tumor cells. In this technique, we have selected 8 apoptotic targets, all of which are active peptides with clear apoptotic and killing effects on tumor cells in international research. Here, we take the function of p53 mutated protein as an example. p53 protein is an important tumor suppressor protein, which is the “cell police”. In healthy human body, it performs the function of monitoring, repairing and apoptosis of “bad cells” in cell growth. When the p53 protein is mutated, these functions are lost, and the “bad cells” can proliferate and grow without restriction, and some of them will form malignant tumors. We use p53 protein C-terminal regulatory peptide and N-terminal regulatory peptide to repair the function of p53 protein and lift the inhibition of p73, the homologous protein of p53, to replace the function of p53 protein to achieve apoptosis and targeted killing of tumor cells, opening up a new therapeutic pathway for malignant tumor treatment. In addition, the combination of protein disulfide bond isomerase bidirectional inhibition peptide, tumor lysing adenovirus tumor killing peptide, chicken anemia virus tumor apoptosis peptide and Par-4 targets to improve the therapeutic effect of tumor killing has become a new approach to tumor biotherapy. Then how to obtain the tumor apoptotic peptide and how can it enter the human body to work? The function of tumor apoptotic peptide has been widely recognized, but the problems of its production, effective concentration in vivo and reaching the effective site of action are the key issues that hinder the clinical application. Firstly, the in vitro synthesis of active peptides is costly and there is a risk of losing the relevant functions; secondly, the active peptides are broken down, metabolized quickly (some only in minutes) and difficult to reach the effective site of action to take effect; it is difficult to produce in large scale and use in clinical treatment. The in vivo secretion and expression of tumor apoptosis active peptide technology with two patents can solve these problems well, it is to introduce the bioactive functional peptide gene into human cells, so that the host cells can independently produce a large number of P53 protein functional repair peptide, tumor-specific apoptosis peptide, protein disulfide bond isomerase two-way inhibition peptide, etc., and enter the target cells through autocrine, paracrine and endocrine mechanisms to play a systemic tumor cell This technology has realized the practical application of tumor apoptosis active peptide in clinical treatment. This technology is suitable for the treatment of patients: a. Patients with solid tumors whose general condition is still acceptable and cannot be controlled by existing therapies. b.Patients with multiple metastases and lack of existing treatment. c.Patients who cannot be treated with chemotherapy or are intolerant to chemotherapy after surgery. d.Patients with solid tumors undergoing anti-relapse therapy after surgery. The tumor apoptosis peptide is artificially encoded using the information encoded at the relevant loci in the human gene pool, and the final functional peptide is a human autologous protein with precise and efficient action. It is effective only on abnormal cells and harmless to normal cells, so it does not have the adverse effects of traditional radiotherapy. A variety of biological peptides developed so far are combined with the patient’s specific situation and used in combination so as to achieve the treatment purpose. This unique treatment mechanism gives many tumor patients whose traditional treatments in big hospitals are ineffective, another brand new treatment option.